A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old

Trial Profile

A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 18 May 2018

At a glance

  • Drugs Tedizolid (Primary) ; Tedizolid (Primary)
  • Indications Gram-positive infections
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 May 2018 Planned End Date changed from 15 Dec 2020 to 22 Mar 2021.
    • 08 May 2018 Planned primary completion date changed from 15 Dec 2020 to 22 Mar 2021.
    • 08 May 2018 Planned initiation date changed from 15 Oct 2018 to 28 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top